Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, Raut S, Kulkarni P, Apte A, Bavdekar A, Bhalla HL, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Pryor M, Hamilton S, Thakar M, Sannidhi RS, Baranwal P, Bhamare C, Dharmadhikari A, Gupta M, Poonawalla CS, Shaligram U, Kapse D; COVOVAX-Booster Study Group. Kulkarni PS, et al. Among authors: bhamare c. Sci Rep. 2023 Oct 3;13(1):16579. doi: 10.1038/s41598-023-43578-w. Sci Rep. 2023. PMID: 37789040 Free PMC article. Clinical Trial.
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, Meshram S, Raut A, Kulkarni P, Samuel C, Munshi R, Gupta M, Plested JS, Cloney-Clark S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Dharmadhikari A, Bhamare C, Shaligram U, Poonawalla CS, Mallory RM, Glenn GM, Kulkarni PS; COVOVAX-Ped study group. Gunale B, et al. Among authors: bhamare c. JAMA Pediatr. 2023 Jul 31;177(9):911-20. doi: 10.1001/jamapediatrics.2023.2552. Online ahead of print. JAMA Pediatr. 2023. PMID: 37523166
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Vadakkedath R, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Shaligram U, Kapse D, Gunale B; COVISHIELD Study Group. Kulkarni PS, et al. Among authors: bhamare c. EClinicalMedicine. 2021 Dec;42:101218. doi: 10.1016/j.eclinm.2021.101218. Epub 2021 Nov 30. EClinicalMedicine. 2021. PMID: 34870133 Free PMC article.
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.
Kulkarni PS, Kadam A, Godbole S, Bhatt V, Raut A, Kohli S, Tripathi S, Kulkarni P, Ludam R, Prabhu M, Bavdekar A, Gogtay NJ, Meshram S, Kadhiravan T, Kar S, Narayana DHA, Samuel C, Kulkarni G, Gaidhane A, Sathyapalan D, Raut S, Hadda V, Bhalla HL, Bhamare C, Dharmadhikari A, Plested JS, Cloney-Clarke S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Gautam M, Gupta N, Panda S, Shaligram U, Poonawalla CS, Bhargava B, Gunale B, Kapse D; COVOVAX Study Group. Kulkarni PS, et al. Among authors: bhamare c. Lancet Reg Health Southeast Asia. 2023 Mar;10:100139. doi: 10.1016/j.lansea.2022.100139. Epub 2023 Jan 11. Lancet Reg Health Southeast Asia. 2023. PMID: 36647543 Free PMC article.
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.
Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, Kapse D, Gunale B, Poonawalla CS, Kulkarni PS. Kang G, et al. Among authors: bhamare c. Lancet Reg Health Southeast Asia. 2023 May 16;14:100207. doi: 10.1016/j.lansea.2023.100207. eCollection 2023 Jul. Lancet Reg Health Southeast Asia. 2023. PMID: 37492421 Free PMC article.
Post-marketing safety surveillance of the rotavirus vaccine in India.
Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, Desai S, Gunale B, Poonawalla CS, Kulkarni PS. Kang G, et al. Among authors: bhamare c. Vaccine X. 2023 Aug 1;15:100362. doi: 10.1016/j.jvacx.2023.100362. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37593522 Free PMC article.
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, Singh K, Munshi R, Meshram S, Selvavinayagam TS, Pandey K, Bhimarasetty DM, Ramakrishnan SR, Bhamare C, Dharmadhikari A, Budhawant C, Bonhomme CJ, Thakar M, Kurle SN, Kelly EJ, Gautam M, Gupta N, Panda S, Bhargava B, Poonawalla CS, Shaligram U, Kapse D, Gunale B. Kulkarni PS, et al. Among authors: bhamare c. Hum Vaccin Immunother. 2024 Dec 31;20(1):2304974. doi: 10.1080/21645515.2024.2304974. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38512394 Free PMC article. Clinical Trial.